Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
A phase 2 trial published in the New England Journal of Medicine showed average weight loss of over 24% at 48 weeks, and the first phase 3 results in December 2025 suggested that average weight loss could be around 28 to 29%
Lamers F, Milaneschi Y, Vinkers CH, Schoevers RA, Giltay EJ, Penninx BWJH
The entire process, from ordering to receiving my medication, has been seamless and easy to navigate
Connor says
For weight management , NICE has approved specific GLP-1 receptor agonists (TA875 for semaglutide 2.4mg/Wegovy
US$ 23.42
US$ 26.38
US$ 23.52
US$ 21.86
